192 related articles for article (PubMed ID: 25189625)
41. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors.
Reeve JG; Morgan J; Schwander J; Bleehen NM
Cancer Res; 1993 Oct; 53(19):4680-5. PubMed ID: 7691401
[TBL] [Abstract][Full Text] [Related]
42. Overview of chemotherapy for small cell lung cancer.
Bunn PA; Carney DN
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-69-S7-74. PubMed ID: 9194484
[TBL] [Abstract][Full Text] [Related]
43. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
[TBL] [Abstract][Full Text] [Related]
44. [Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
Su Y
Ai Zheng; 2006 Dec; 25(12):1569-72. PubMed ID: 17166389
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer.
Arúajo AM; Mendez JC; Coelho AL; Sousa B; Barata F; Figueiredo A; Amaro T; Azevedo I; Soares M
Cancer Invest; 2009 May; 27(4):391-6. PubMed ID: 19266367
[TBL] [Abstract][Full Text] [Related]
46. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
Kim SJ; Kim JS; Kim SC; Kim YK; Kim YK; Kang JY; Yoon HK; Song JS; Lee SH; Moon HS; Kim JW; Kim KH; Kim CH; Shim BY; Kim HK
Lung Cancer; 2010 Jun; 68(3):446-9. PubMed ID: 19683359
[TBL] [Abstract][Full Text] [Related]
47. Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system.
Jhun BW; Lee KJ; Jeon K; Suh GY; Chung MP; Kim H; Kwon OJ; Sun JM; Ahn JS; Ahn MJ; Park K; Choi JY; Lee KS; Han J; Um SW
Lung Cancer; 2013 Jul; 81(1):65-70. PubMed ID: 23523420
[TBL] [Abstract][Full Text] [Related]
48. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
50. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy.
Giuliani ME; Atallah S; Sun A; Bezjak A; Le LW; Brade A; Cho J; Leighl NB; Shepherd FA; Hope AJ
Clin Lung Cancer; 2011 Nov; 12(6):375-9. PubMed ID: 21729647
[TBL] [Abstract][Full Text] [Related]
51. Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer.
Shepherd FA
Semin Oncol; 2001 Apr; 28(2 Suppl 4):30-7. PubMed ID: 11479895
[TBL] [Abstract][Full Text] [Related]
52. Ganetespib for small cell lung cancer.
Subramaniam DS; Warner EA; Giaccone G
Expert Opin Investig Drugs; 2017 Jan; 26(1):103-108. PubMed ID: 27922280
[TBL] [Abstract][Full Text] [Related]
53. [Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer].
Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):624-628. PubMed ID: 32867452
[TBL] [Abstract][Full Text] [Related]
54. Small cell lung cancer: will recent progress lead to improved outcomes?
Pietanza MC; Byers LA; Minna JD; Rudin CM
Clin Cancer Res; 2015 May; 21(10):2244-55. PubMed ID: 25979931
[TBL] [Abstract][Full Text] [Related]
55. DLL3: an emerging target in small cell lung cancer.
Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
[TBL] [Abstract][Full Text] [Related]
56. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
Mak DWS; Li S; Minchom A
Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
[TBL] [Abstract][Full Text] [Related]
57. Targeting hypoxia in the treatment of small cell lung cancer.
Bryant JL; Meredith SL; Williams KJ; White A
Lung Cancer; 2014 Nov; 86(2):126-32. PubMed ID: 25201720
[TBL] [Abstract][Full Text] [Related]
58. Current and future therapeutic approaches for the treatment of small cell lung cancer.
Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
[TBL] [Abstract][Full Text] [Related]
59. Novel formulations and new mechanisms of delivering chemotherapy.
Stinchcombe TE
Am Soc Clin Oncol Educ Book; 2014; ():e381-6. PubMed ID: 24857128
[TBL] [Abstract][Full Text] [Related]
60. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
